Immunotherapy in Ovarian Cancer
Volume 1 - Issue 3
Satyendra C Tripathi*
-
Author Information
Open or Close
- Department of Clinical Cancer Prevention, University of Texas at Austin, USA
*Corresponding author:
Satyendra C Tripathi, Department of Clinical Cancer Prevention, University of Texas at Austin, The University of
Texas MD Anderson cancer Center, 6767 Bertner Avenue, Houston Texas-77030, USA
Received: January 10, 2018; Published: January 24, 2018
DOI: 10.32474/IGWHC.2018.01.000112
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Ovarian cancer ranks fifth with a 5-year survival of 40%
for patients with advanced disease and remains the most lethal
gynecologic malignancy among women [1]. Most patients with
advanced disease undergo aggressive frontline treatments with
surgery and adjuvant chemotherapy; however, 80% of patients
ultimately recur within few months and develop chemoresistant
disease [2]. Advances in traditional treatment regimens and
addition bevacizumab as a targeted therapy have shown promising
results with improved progression-free survival but overall survival
rates still remains the unaltered.
Editorial|
References|